Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States; One-Health Vision Research Program, Departments of Veterinary Medicine & Surgery and Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia, MO, United States.
Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States; One-Health Vision Research Program, Departments of Veterinary Medicine & Surgery and Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia, MO, United States; Mason Eye Institute, School of Medicine, University of Missouri, Columbia, MO, United States.
Exp Eye Res. 2021 Jun;207:108610. doi: 10.1016/j.exer.2021.108610. Epub 2021 Apr 30.
Our earlier decorin (Dcn) gene overexpression studies found that the targeted Dcn gene transfer into the cornea inhibited corneal angiogenesis in vivo using a rabbit model. In this study, we tested the hypothesis that anti-angiogenic effects of decorin in the cornea are mediated by alterations in a normal physiologic balance of pro- and anti-angiogenic factors using decorin deficient (Dcn) and wild type (Dcn) mice. Corneal neovascularization (CNV) in Dcn and Dcn mice was produced with a standard chemical injury technique. The clinical progression of CNV in mice was monitored with stereo- and slit-lamp microscopes, and histopathological hematoxylin and eosin (H&E) staining. Protein and mRNA expression of pro- and anti-angiogenic factors in the cornea were evaluated using immunofluorescence and quantitative real-time PCR, respectively. Slit-lamp clinical eye examinations revealed significantly more CNV in Dcn mice than the Dcn mice post-injury (p < 0.05) and AAV5-Dcn gene therapy significantly reduced CNV in Dcn mice compered to no AAV5-Dcn gene therapy controls (p < 0.001). H&E-stained corneal sections exhibited morphology with several neovessels in injured corneas of the Dcn mice than the Dcn mice. Immunofluorescence of corneal sections displayed significantly higher expression of α-smooth muscle actin (α-SMA) and endoglin proteins in Dcn mice than Dcn mice (p < 0.05). Quantitative real-time PCR found significantly increased mRNA levels of pro-angiogenic factors endoglin (2.53-fold; p < 0.05), Vegf (2.47-fold; p < 0.05), and Pecam (2.14-fold; p < 0.05) and anti-angiogenic factor Vegfr2 (1.56-fold; p < 0.05) in the normal cornea of the Dcn mice than the Dcn mice. Furthermore, neovascularized Dcn mice corneas showed greater increase in mRNA expression of pro-angiogenic factors endoglin (4.58-fold; p < 0.0001), Vegf (4.16-fold; p < 0.0001), and Pdgf (2.15-fold; p < 0.0001) and reduced expression of anti-angiogenic factors Ang2 (0.12-fold; p < 0.05), Timp1 (0.22-fold; p < 0.05), and Vegfr2 (0.67-fold; p > 0.05) compared to neovascularized Dcn mice corneas. These gene deficience studies carried with transgenic Dcn mice revealed decorin's role in influencing a physiologic balance between pro-and anti-angiogenic factors in the normal and injured cornea. We infer that the functional deletion of Dcn promotes irregular corneal repair and aggravates CNV.
我们之前的核心蛋白聚糖(Dcn)基因过表达研究发现,使用兔模型,将靶向 Dcn 基因转移到角膜中可抑制体内角膜血管生成。在这项研究中,我们使用核心蛋白聚糖缺乏(Dcn)和野生型(Dcn)小鼠测试了这样一个假设,即核心蛋白聚糖在角膜中的抗血管生成作用是通过改变正常的促血管生成和抗血管生成因子的生理平衡来介导的。使用标准的化学损伤技术在 Dcn 和 Dcn 小鼠中产生角膜新生血管(CNV)。使用立体显微镜和裂隙灯显微镜监测小鼠 CNV 的临床进展,并进行苏木精和伊红(H&E)染色的组织病理学检查。使用免疫荧光和定量实时 PCR 分别评估角膜中促血管生成和抗血管生成因子的蛋白和 mRNA 表达。裂隙灯临床眼部检查显示,与 Dcn 小鼠相比,Dcn 小鼠的 CNV 明显更多(p < 0.05),并且 AAV5-Dcn 基因治疗可显著减少 Dcn 小鼠的 CNV,与无 AAV5-Dcn 基因治疗对照相比(p < 0.001)。H&E 染色的角膜切片显示,与 Dcn 小鼠相比,Dcn 小鼠受伤角膜中有更多的新生血管。角膜切片的免疫荧光显示,Dcn 小鼠中 α-平滑肌肌动蛋白(α-SMA)和内源性蛋白的表达明显高于 Dcn 小鼠(p < 0.05)。定量实时 PCR 发现,Dcn 小鼠正常角膜中促血管生成因子内源性蛋白(2.53 倍;p < 0.05)、Vegf(2.47 倍;p < 0.05)和 Pecam(2.14 倍;p < 0.05)和抗血管生成因子 Vegfr2(1.56 倍;p < 0.05)的 mRNA 水平明显升高。此外,新生血管化的 Dcn 小鼠角膜中促血管生成因子内源性蛋白(4.58 倍;p < 0.0001)、Vegf(4.16 倍;p < 0.0001)和 Pdgf(2.15 倍;p < 0.0001)的 mRNA 表达增加更大,抗血管生成因子 Ang2(0.12 倍;p < 0.05)、Timp1(0.22 倍;p < 0.05)和 Vegfr2(0.67 倍;p > 0.05)的表达减少。与新生血管化的 Dcn 小鼠角膜相比。这些带有转基因 Dcn 小鼠的基因缺陷研究揭示了核心蛋白聚糖在影响正常和受伤角膜中促血管生成和抗血管生成因子之间生理平衡方面的作用。我们推断,Dcn 的功能缺失会促进不规则的角膜修复并加重 CNV。
Exp Eye Res. 2021-6
Transl Vis Sci Technol. 2021-8-12
Invest Ophthalmol Vis Sci. 2006-5
Invest Ophthalmol Vis Sci. 2012-6-14
Cells. 2024-6-26
Proc Natl Acad Sci U S A. 2024-4-30
iScience. 2023-10-4
Exp Eye Res. 2019-6-18
Ocul Surf. 2018-6-20
FASEB J. 2018-1-11
Chem Biol Drug Des. 2017-11
Matrix Biol. 2015-4
Arterioscler Thromb Vasc Biol. 2015-4
Graefes Arch Clin Exp Ophthalmol. 2015-2